Abstract PO2-18-02: Utilization of Granulocyte Colony-Stimulating Factor (GCSF) in the Management of Patients (pts) on Sacituzumab Govitecan-hziy (SG) and Impact on Duration of Therapy (DOT)
Authors: Gorantla Vikram , Alwon Erin , Gart Mike , Li John , Blanc Simon , Brenneman Dawn , Genser Emma , Varughese Prateesh , Scott Justin , Katzen Harvey 
Published: May 2024

Abstract
Background: An examination was conducted to understand the prevalence of neutropenia in pts managed with SG in the real-world setting, as the ASCENT trial demonstrated a 63% rate of neutropenia in those pts treated with SG1. In addition, an assessment was performed to see whether pts who developed neutropenia on SG received a GCSF and how GCSF use impacted pt DOT on SG.
Methods: This assessment utilized the Integra Connect PrecisionQ real-world de-identified database of over 2 million cancer pts across 500 sites of care to evaluate the prevalence of neutropenia (&lt; 1500 neutrophils) among those who were treated with SG, GCSF utilization among those with neutropenia, and the difference in DOT between neutropenic pts who received a GCSF and those who did not. In analyzing the DOT, pts were required to have had a follow-up of 12 months or greater. The SG pts data utilized reflects treatments through May 31, 2023. Comparisons of median DOT were conducted using a Wilcoxon Rank Sum test. Descriptive analyses were used to summarize pt demographic statistics.
Results: 447 pts treated with SG were identified with an average age at treatment start of 58.5 (median of 60); 15% identified as Black or African American and 69% identified as White or Caucasian. Of the 447 pts treated with SG, 98% (N = 438) developed neutropenia while on therapy. Among those 438 pts who developed neutropenia, 61% received a GCSF and 39% did not. Of the 330 pts with at least 12 months of follow-up, the median DOT was 119.5 days. Among the 204 pts who received a GCSF, the median DOT was 147 days, compared to a median DOT of 97 days for the 126 pts who did not receive a GCSF (p &lt; 0.001).
Conclusion: The DOT for pts treated with SG who received a GCSF was longer than those who did not receive a GCSF while treated with SG. This assessment revealed that approximately 40% of SG treated pts who developed neutropenia did not receive a GCSF. Thus, increasing utilization of GCSFs presents an opportunity to improve management of pts who develop neutropenia while on SG to extend the time on therapy and potentially delay disease progression. These findings warrant further research on the use of prophylactic GCSFs for managing pts who receive SG and suggest further clinical guidance may be needed to provide best practices for managing pts on SG.
[1] Rugo, H.S., Tolaney, S.M., Loirat, D. et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. npj Breast Cancer 8, 98 (2022). https://doi.org/10.1038/s41523-022-00467-1
Citation Format: Vikram Gorantla, Erin Alwon, Mike Gart, John Li, Simon Blanc, Dawn Brenneman, Emma Genser, Prateesh Varughese, Justin Scott, Harvey Katzen. Utilization of Granulocyte Colony-Stimulating Factor (GCSF) in the Management of Patients (pts) on Sacituzumab Govitecan-hziy (SG) and Impact on Duration of Therapy (DOT) [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-18-02.